Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC

Introduction: ECOG-ACRIN E1505 was a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with stages IB (>4 cm) to IIIA NSCLC. We sought to estimate the incidence and risk factors for brain recurrence as compared with extracranial recurrences (ECRs). Methods...

Full description

Bibliographic Details
Main Authors: John M. Varlotto, MD, Yating Wang, MS, Zhuoxin Sun, PhD, Heather A. Wakelee, MD, Suresh Ramalingam, MD, Joan Schiller, MD
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:JTO Clinical and Research Reports
Subjects:
Brain metastases
Non–small cell lung cancer
Adjuvant therapy
Bevacizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001338

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321001338

Similar Items